23.01.2020 17:00Different type of contracts & deals in life science: Deal structuration workshop with Zaki Sellam & Laurence De Schoulepnikoff
Cost: Free, limited to 20 people
From a start-up perspective, before engaging into any deal with a potential partner, it is important to have already an idea about the potential deal structure and possibilities. Being able to differenciate the implications, PROs and CONs between various type of deal structures is not a given. It constitutes on multiple occasions a point of confusion and misunderstanding between parties. So the aim of the session will be to not only describe each type of deal (options, license, equity investment, asset purchace, research agreement…) but also to have a simple framework and decision guide for entrepreneurs.
ZAKI SELLAM, CEO Avicenna Oncology GmbH & Corporate Strategy Advisor in Biotech
With more than 15 years of international experience, Zaki has been diving mainly in the Biotech arena.
As an entrepreneur, he is involved in the creation of a few start-up oncology and immunology across Europe. For instance, he founded Avicenna Oncology GmbH, Immuno-Oncology and Antibody Drug Conjugate start-up in, Basel, Switzerland. Another instance is the current role as Chief Operations Officer of ATIcure (Basel based start-up in T cell therapy), helping the inventors to set up the company from scratch.
Aside his entrepreneurial activities, Zaki is advising several Start-up, Tech Transfer Accelerators and Pharma companies through ESN Life Sciences GmbH (his consulting firm). Zaki’s expertise is appreciated because he can bring both a 360 degree & entrepreneurial perspective on all aspects ranging from science (immunology, oncology) to translational & clinical development, corporate strategy, financing & partnering.
Zaki holds a Master of Science degree in Biotechnology Engineering from the National School of Biotechnology in Bordeaux, France, and a Master of Business Administration from the Institute of Business Administration from Poitiers, France. He is also in the late stage of a part time PhD in Strategic Management (supervised by Prof Brian Smith, Hertfordshire Business School, United Kingdom) in the understanding and conceptualization of “Deal structuration between within the R&D context of Biopharma”. He is a native French speaker, fluent in English & Spanish, and Intermediate in German and Arabic.
LAURENCE DE SCHOULEPNIKOFF, Chief Operating Officer at Amal Therapeutics
Laurence has over twenty-five years of professional experience with broad expertise in business development and transactions in the pharmaceutical industry, in particular in structuring and negotiating licensing-in/out and acquisition/divestment deals. She benefits from an in-depth understanding of the strategic and financial drivers as well as the regulatory and legal environment. She has a strong scientific background with extensive experience in alliance management, strategic sourcing and supply chain. Laurence joined AMAL Therapeutics in January 2019.